ADVENTRX Meets Primary Endpoint In ANX-530 Marketing-Enabling Clinical Study (Medical News Today)

ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced positive results from its marketing enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine(R), the reference product, in patients with advanced cancer potentially sensitive to vinorelbine. [click link for full article]

(more)

Need money for your business? How about an unsecured business line of credit?
Visit WSCF Business Loans for more information.